---
figid: PMC3926869__onci-2-e26961-g1
figtitle: Immunosuppressants in cancer prevention and therapy
organisms:
- Human gammaherpesvirus 4
- Human papillomavirus
- Human betaherpesvirus 5
- Myxoma virus
- Saccharomyces cerevisiae
- Drosophila melanogaster
- Caenorhabditis elegans
- Nicotiana tabacum
- Homo sapiens
- Mus musculus
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC3926869
filename: onci-2-e26961-g1.jpg
figlink: /pmc/articles/PMC3926869/figure/F1/
number: F1
caption: Figure 1. The mTOR pathway is involved in both cancer and senescence. Growth
  factors, cytokines, insulin, nutrients, and oncoproteins activate the phosphoinositide-3-kinase/mammalian
  target of rapamycin (PI3K/mTOR) signaling pathway, which promotes cellular growth
  and cell cycle progression. Mutations that results in constitutive activation of
  the mTOR pathway are involved in oncogenic transformation when intrinsic controls
  on cell cycle progression are disabled. Conversely, when mTOR is activated and the
  cell cycle is arrested, cells enter a senescent state. Rapamycin and other rapalogs
  (e.g., everolimus) inhibit the mTOR complex 1 (mTORC1) and suppress such a geroconversion.
papertitle: Immunosuppressants in cancer prevention and therapy.
reftext: Mikhail V Blagosklonny. Oncoimmunology. 2013 Dec 1;2(12):e26961.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9398514
figid_alias: PMC3926869__F1
figtype: Figure
redirect_from: /figures/PMC3926869__F1
ndex: 16f2eb71-de9a-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3926869__onci-2-e26961-g1.html
  '@type': Dataset
  description: Figure 1. The mTOR pathway is involved in both cancer and senescence.
    Growth factors, cytokines, insulin, nutrients, and oncoproteins activate the phosphoinositide-3-kinase/mammalian
    target of rapamycin (PI3K/mTOR) signaling pathway, which promotes cellular growth
    and cell cycle progression. Mutations that results in constitutive activation
    of the mTOR pathway are involved in oncogenic transformation when intrinsic controls
    on cell cycle progression are disabled. Conversely, when mTOR is activated and
    the cell cycle is arrested, cells enter a senescent state. Rapamycin and other
    rapalogs (e.g., everolimus) inhibit the mTOR complex 1 (mTORC1) and suppress such
    a geroconversion.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Crtc
  - CycE
  - cyc
  - mas
  - myoblast-specific
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MTOR
  - RPTOR
  - FBN1
---
